Please assess the completion status of the following clinical trial:

Trial Title: Olanzapine for Nausea After Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults age ≥ 18 and ≤ 50 years old~* Patient scheduled to undergo ambulatory surgery under general anesthesia~* Willing and able to provide informed consent~Exclusion Criteria:~* Unable to swallow pills~* Current use of typical or atypical anti-psychotic medications~* History of allergy to olanzapine~* Pregnancy/Lactation (subjects of child-bearing potential will have a urine pregnancy test performed the day of surgery)~* History of QTc \> 450ms or torsades de pointes~* Current use of antihypertensive medication~* Diabetes Mellitus~* Clinically significant cardiovascular disease defined as follows:~  1. Myocardial infarction or unstable angina within 6 months prior to the day of planned surgery.~ 2. History of serious ventricular arrhythmia (i.e.: ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications, except for atrial fibrillation that is well controlled on anti-arrhythmic medication.~ 3. New York Heart Association (NYHA) Class II or higher congestive heart failure.~* Postural hypotension or vasovagal syncope within 6 months of planned surgery.~* Hypotension on day of surgery, defined as a systolic blood pressure \< 90mm Hg or a diastolic pressure \< 60mm Hg.~* Seizure disorder~* Clinically active prolactinoma~* Hepatic disease~* Poorly controlled diabetes~* Pre-operative blood glucose \> 250 mg/dL~* Narrow angle glaucoma~* Parkinson's disease~* Lewy body dementia

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Olanzapine (Type: EXPERIMENTAL): 10mg pill
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).